Thiorphan enhances bradykinin-induced vascular relaxation in hypoxic/hyperkalaemic porcine coronary artery

被引:7
作者
Krassói, I
Pataricza, J
Papp, JG
机构
[1] Univ Szeged, Hungarian Acad Sci, Div Cardiovasc Pharmacol, H-6701 Szeged, Hungary
[2] Univ Szeged, Albert Szent Gyorgyi Med Ctr, Dept Pharmacol & Pharmacotherapy, H-6701 Szeged, Hungary
关键词
D O I
10.1211/002235702667
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Relaxation induced by bradykinin is diminished by hypoxia in epicardial coronary arteries. The bradykinin-degrading enzyme, neutral endopeptidase (NEP, EC.3.4.24.11), is a potential target for coronary artery vasodilators. In this study, we examined the effect of thiorphan, an inhibitor of NEP, on the tone of porcine isolated coronary artery under hypoxic conditions. Endothelium-intact porcine isolated coronary artery rings were isometrically contracted with a prostaglandin F-2alpha, analogue (U46619, 0.75 muM) and potassium chloride (KCl, 30 mm), and relaxed with bradykinin (1-1000 nm) under normoxic (partial pressure of oxygen, Po-2 similar to 90-100 mmHg) and moderately hypoxic (pO(2) similar to 50-60 mmHg) conditions. Experiments were performed to study the effects of 30 min pre-treatment with the NEP-inhibitor, thiorphan (10 muM), both at physiological and at low Po(2)s. Hypoxia inhibited the bradykinin-induced relaxation in porcine epicardial coronary arteries. In normoxia, thiorphan significantly enhanced the decrease of coronary tone produced by bradykinin (1-10 nm) when U46619 was used as contractile agent. Under hypoxic conditions, in U46619 contracture, thiorphan did not influence, but in KCl contracture it enhanced the magnitude of relaxations induced by bradykinin. In the absence of bradykinin, thiorphan had no significant effect on the basal, KCl- and U46619-elevated tones and on the hypoxia-induced decrease of coronary artery tone. Inhibition of NEP-enzyme activity may effectively improve the relaxing capacity of epicardial coronary arteries under hypoxic/hyperkalemic conditions. This effect could be potentially utilized when the endothelial function and relaxation of the coronary arteries are impaired under clinical conditions.
引用
收藏
页码:339 / 345
页数:7
相关论文
共 20 条
[1]  
Blais C, 2000, J PHARMACOL EXP THER, V295, P621
[2]   Endothelial dysfunction in human disease [J].
Drexler, H ;
Hornig, B .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1999, 31 (01) :51-60
[3]   Metabolism of bradykinin by the rat coronary vascular bed [J].
Dumoulin, MJ ;
Adam, A ;
Blais, C ;
Lamontagne, D .
CARDIOVASCULAR RESEARCH, 1998, 38 (01) :229-236
[4]   Endothelium-derived hyperpolarizing factor synthase (cytochrome P4502C9) is a functionally significant source of reactive oxygen species in coronary arteries [J].
Fleming, I ;
Michaelis, UR ;
Bredenkötter, D ;
Fisslthaler, B ;
Dehghani, F ;
Brandes, RP ;
Busse, R .
CIRCULATION RESEARCH, 2001, 88 (01) :44-51
[5]   DEPENDENCE OF ENDOTHELIUM-MEDIATED RELAXATION ON OXYGEN AND METABOLISM IN PORCINE CORONARY-ARTERIES [J].
HASHIMOTO, M ;
CLOSE, LA ;
ISHIDA, Y ;
PAUL, RJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (01) :H299-H306
[6]   Hyperkalemia alters endothelium-dependent relaxation through non-nitric oxide and noncyclooxygenase pathway: A mechanism for coronary dysfunction due to cardioplegia [J].
He, GW ;
Yang, CQ .
ANNALS OF THORACIC SURGERY, 1996, 61 (05) :1394-1399
[7]   Myocardial protection during cardiac surgery from the viewpoint of coronary endothelial function [J].
He, GW .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1999, 26 (10) :810-814
[8]   Mechanisms of bradykinin-induced relaxation in pig coronary arteries [J].
Hernanz, R ;
Alonso, MJ ;
Baena, AB ;
Salaices, M ;
Marín, J .
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1999, 21 (04) :243-251
[9]   Possible biphasic changes of free radicals in ethylene glycol-induced nephrolithiasis in rats [J].
Huang, HS ;
Chen, CF ;
Chien, CT ;
Chen, J .
BJU INTERNATIONAL, 2000, 85 (09) :1143-1149
[10]   Novel neurohormonal modulators in cardiovascular disorders. The therapeutic potential of endopeptidase inhibitors. [J].
Kentsch M. ;
Otter W. .
Drugs in R & D, 1999, 1 (4) :331-338